about
Capturing Biological Activity in Natural Product Fragments by Chemical SynthesisCrystal Structure of MraY, an Essential Membrane Enzyme for Bacterial Cell Wall SynthesisAssessing HTS performance using BioAssay Ontology: screening and analysis of a bacterial phospho-N-acetylmuramoyl-pentapeptide translocase campaign.Highly efficient O-glycosylations with p-tolyl thioribosides and p-TolSOTf.Amino acid motifs in natural products: synthesis of O-acylated derivatives of (2S,3S)-3-hydroxyleucine.A high-throughput, homogeneous, fluorescence resonance energy transfer-based assay for phospho-N-acetylmuramoyl-pentapeptide translocase (MraY).Biosynthesis of a water-soluble lipid I analogue and a convenient assay for translocase I.A reliable Pd-mediated hydrogenolytic deprotection of BOM group of uridine ureido nitrogenA new protecting group and linker for uridine ureido nitrogen.Fluorescence-based assay for polyprenyl phosphate-GlcNAc-1-phosphate transferase (WecA) and identification of novel antimycobacterial WecA inhibitors.Total Synthesis of Dansylated Park's Nucleotide for High-Throughput MraY Assays.Lipid intermediates in the biosynthesis of bacterial peptidoglycanThe muraminomicin biosynthetic gene cluster and enzymatic formation of the 2-deoxyaminoribosyl appendage.Polymer-supported (2,6-dichloro- 4-alkoxyphenyl)(2,4-dichlorophenyl)methanol: a new linker for solid-phase organic synthesis.The biosynthesis of peptidoglycan lipid-linked intermediates.Advances in MRSA drug discovery: where are we and where do we need to be?Stereocontrolled Total Synthesis of Muraymycin D1 Having a Dual Mode of Action against Mycobacterium tuberculosis.Improved synthesis of capuramycin and its analogues.Peptidoglycan biosynthesis machinery: a rich source of drug targets.Recent derivatives from smaller classes of fermentation-derived antibacterials.Navigating tuberculosis drug discovery with target-based screening.Viable screening targets related to the bacterial cell wall.Update on carbohydrate-containing antibacterial agents.Mycobacterial cell wall biosynthesis: a multifaceted antibiotic target.Concise synthesis of capuramycin.Structural Investigation of Park's Nucleotide on Bacterial Translocase MraY: Discovery of Unexpected MraY Inhibitors.Identification and manipulation of the caprazamycin gene cluster lead to new simplified liponucleoside antibiotics and give insights into the biosynthetic pathway.Minimal requirements for inhibition of MraY by lysis protein E from bacteriophage ΦX174.Mechanism of action of the uridyl peptide antibiotics: an unexpected link to a protein-protein interaction site in translocase MraY.Molecular cloning and identification of the laspartomycin biosynthetic gene cluster from Streptomyces viridochromogenes.Quinovosamycins: new tunicamycin-type antibiotics in which the α, β-1″,11'-linked N-acetylglucosamine residue is replaced by N-acetylquinovosamine.MraY-antibiotic complex reveals details of tunicamycin mode of action.Insights into the Target Interaction of Naturally Occurring Muraymycin Nucleoside Antibiotics.Function-Oriented Synthesis: How to Design Simplified Analogues of Antibacterial Nucleoside Natural Products?5'-Methylene-triazole-substituted-aminoribosyl uridines as MraY inhibitors: synthesis, biological evaluation and molecular modeling.Total Synthesis of (−)-Caprazamycin ATotal Synthesis of (−)-Caprazamycin APlatinum catalyzed 7-endo cyclization of internal alkynyl amides and its application to synthesis of the caprazamycin coreStructures of DPAGT1 Explain Glycosylation Disease Mechanisms and Advance TB Antibiotic Design
P2860
Q26772873-0C13A5C3-933F-43C9-9D28-D3DA57ABD943Q27679836-8CC34470-428E-45E5-817E-BB7713F51BB7Q30397082-58E8260D-3DE0-4CD8-BDC7-674546F2740AQ33368397-5050197E-C770-45F0-97F5-A00089BD14A9Q33829573-AFE0EB94-8ED6-4A03-9BBE-2D800388D69CQ34159994-18BB0E8F-997C-4DAD-914A-9F0CD498A9C8Q34976154-8301755B-6BC5-4706-9689-0AE4373447A9Q36033749-3ACD6DCF-2D4E-4BAF-A7E1-79223F6FCC11Q36033759-A7E7C2D7-3A8C-4801-BA5C-F68CF0EFCAD5Q36105224-0D9B758E-A560-41C6-AF78-EB28E569AEC6Q36176949-1E2D2181-9DF9-43E1-AA51-447ACBC8104AQ36314747-D1376458-CC47-4277-A140-9BFBF142CCEEQ36657600-66A373DC-EEFD-42C8-B899-A780717477BEQ36959470-71B2A317-4B4C-46B9-A8C3-E1EEB78DD5DEQ37032866-CCB38C96-006E-47C7-B044-A4DF91C8CC74Q37112508-E1758309-6148-4E7D-8A17-7546891857B6Q37317850-4D298A50-1436-49D5-84D4-8FE5CF11DDBEQ37594561-DF0A869D-B51D-4474-8467-9640BF5980F4Q37810971-92AD34CE-DEA6-4ADE-B26A-9FD8B67398A9Q37964009-DDB3BAD3-AED0-418B-AEC8-A41720F7834DQ38014956-7948A473-0333-40F5-AC17-FBB61AB5DF67Q38070780-A4C63F4D-5972-4354-8379-02E57CAC68FFQ38089193-72919B3A-7FD4-42E0-878A-1090F490AE61Q38782638-EB525BBB-7BE2-4420-934B-A3CC28DA1173Q38872743-F0098E20-759A-4BDA-B59E-DEFFE56DB241Q41729149-326A0C2B-4489-4718-B07C-4F7869A26120Q41902103-CEA049AA-C562-4053-83B1-AE57A2488AFFQ42072783-047E83AA-58F2-4034-B0E9-6F12DFDB1190Q42187998-7A4D4641-15D1-4A8A-88A0-78A482FC833CQ42228528-3C0CE547-28A2-4140-9758-26C007922D53Q46400754-0F70F910-1497-4B41-9819-FF8724EE1FB9Q48371964-84F710E9-7661-46A1-AA80-D6EE4B096395Q50041268-B9BB8ECA-5C19-4A8A-8B6F-AB96546A8057Q50865707-8BE30F0B-5CC3-43DB-81EF-27465E839434Q53841671-E1548B68-5D19-4304-AC00-15E49D66F9DBQ57749491-EB001078-C52C-47A1-AA8B-02097DA3CEC8Q57749495-4E08A383-C865-4F42-BB6B-6C1666FA87EDQ57749529-D951759F-2278-4DD6-B1A8-7240B1E4CC55Q58547177-302B3427-20DD-46A6-B670-DDDD45DBE32E
P2860
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
MraY Inhibitors as Novel Antibacterial Agents.
@ast
MraY Inhibitors as Novel Antibacterial Agents.
@en
type
label
MraY Inhibitors as Novel Antibacterial Agents.
@ast
MraY Inhibitors as Novel Antibacterial Agents.
@en
prefLabel
MraY Inhibitors as Novel Antibacterial Agents.
@ast
MraY Inhibitors as Novel Antibacterial Agents.
@en
P1476
MraY Inhibitors as Novel Antibacterial Agents.
@en
P2093
Christophe Dini
P304
P356
10.2174/156802605774463042
P577
2005-01-01T00:00:00Z